Aijaz Javeria, Khan Jibran, Naseer Fouzia, Kumar Dheeraj, Hussain Shakir
Molecular Biology Section, Pathology Department, Indus Hospital & Health Network, Korangi Crossing, Karachi, 75190, Pakistan.
Pract Lab Med. 2023 Jul 7;36:e00326. doi: 10.1016/j.plabm.2023.e00326. eCollection 2023 Aug.
To verify the analytical performance of cobas® HBV PCR and cobas® HCV PCR assays with Abbott m2000 RealTime System as the reference method.
De-identified residual, archived patient specimens, and College of American Pathologists (CAP) proficiency testing samples were used. Analytical parameters verified were accuracy, precision, limit of detection (LOD), linear range, and cross-contamination. Experiments were designed in accordance with Clinical Laboratories Standards Institute (CLSI) guidelines and CAP standards. Analysis of accuracy was done through regression plots and Bland Altman analyses. Precision was analyzed through coefficient of variation and ANOVA; LOD through probit analysis; and linear range through polynomial fit analysis.
The regression plots for accuracy showed a slope nearing 1, with a y-intercept close to zero, while Bland Altman analyses also showed no systematic evidence of bias, though concordance of results was not perfect near the lower limit of quantification. Coefficients of variation were all below 15%, while ANOVA returned p-values above 0.99, indicating no statistically significant imprecision. The LOD verified were an order of magnitude higher than the manufacturer reported ones for both assays, while the linear range verified was more limited. Within the verified range, polynomial fit analysis showed line to be the best fit for the data.
cobas® HBV PCR and cobas® HCV PCR assays showed acceptable accuracy, acceptable precision, as well as no evidence of cross-contamination. The LOD verified were higher, and linear ranges more limited than those reported by the manufacturer. Verifications of these may be limited by availability of appropriate testing specimens.
以雅培m2000实时荧光定量分析仪作为参考方法,验证cobas® HBV PCR和cobas® HCV PCR检测方法的分析性能。
使用经过去识别化处理的残留存档患者样本以及美国病理学家协会(CAP)能力验证样本。验证的分析参数包括准确性、精密度、检测限(LOD)、线性范围和交叉污染。实验按照临床实验室标准协会(CLSI)指南和CAP标准进行设计。通过回归图和布兰德-奥特曼分析进行准确性分析。通过变异系数和方差分析(ANOVA)分析精密度;通过概率分析确定检测限;通过多项式拟合分析确定线性范围。
准确性的回归图显示斜率接近1,截距接近零,而布兰德-奥特曼分析也未显示出系统性偏差证据,不过在定量下限附近结果的一致性并不完美。变异系数均低于15%,方差分析得出的p值高于0.99,表明不存在统计学上显著的不精密度。验证得到的两种检测方法的检测限均比制造商报告的高一个数量级,而验证得到的线性范围更有限。在验证范围内,多项式拟合分析表明线性最适合数据。
cobas® HBV PCR和cobas® HCV PCR检测方法显示出可接受的准确性、可接受的精密度,且没有交叉污染的证据。验证得到的检测限更高,线性范围比制造商报告的更有限。这些验证可能受到合适检测样本可用性的限制。